Search

Displaying results 8011 - 8020 of 10000 in total
  1. Drug

    Ticalopride

    go.drugbank.com/drugs/DB06422
    Experimental

  2. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours.

  3. Drug

    XL999

    go.drugbank.com/drugs/DB05014
    Investigational

    XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models. … XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3.

  4. Drug

    Olenasufligene relduparvovec

    go.drugbank.com/drugs/DB16264
    Investigational

    It is an adeno-associated virus (AAV) vector that delivers a functional copy of the human SGSH gene.[L46671]

  5. Drug

    VTX-801

    go.drugbank.com/drugs/DB17646
    Investigational

    VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the

  6. Drug

    EGT-301

    go.drugbank.com/drugs/DB17649
    Experimental

    EGT-301 is a gene therapy being investigated for Hunter Syndrome. … It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome

  7. Drug

    Coagulin-B

    go.drugbank.com/drugs/DB17703
    Experimental

    Coagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX.

  8. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    As a result, CT-322 blocks all known ligands for VEGFR-2. … CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis

  9. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel. … ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

  10. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. … PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.